Non-Alcoholic Steatohepatitis Biomarkers Market Landscape
The arrival of the novel Coronavirus pandemic is anticipated to create significant roadblocks for companies working in the current non-alcoholic steatohepatitis (NASH) biomarkers market. But at the same time and according to the latest study conducted by Market Research Future, global non-alcoholic steatohepatitis (NASH) biomarkers market is expected to grow at a staggering CAGR of ~20.92% in the course of period 2016–2024. Also, during this course of growth, the market would be achieving revenue of USD 1,960.4 million with ongoing rising healthcare industry activities and importance.
Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7984
(***MRFR FREE SAMPLE COPY of the Report Gives a Brief Introduction to the Research Report, Industry Insight, Size and Forecast, Drivers, Challenges, Trends, Including COVID19 Impact Analysis, Full TOC (123 pages with 143 data tables and 34 figures of the report), an Analysis of the Industry Key Players and comprising Key Regions.***)
Non-Alcoholic Steatohepatitis Biomarkers Market Growth & Attributes
Non-alcoholic steatohepatitis is a superior stage of non-alcoholic fatty liver disease (NAFLD), which arises mainly during the excess fat accumulation and causes inflammation and damage, leading to liver scarring. A biomarker is the most useful diagnostic tool for measuring the biological state and is termed as a pointer for measuring normal biological processes and pathogenic processes in the body. Biomarker tools accessible for diagnosing NASH conditions are known as non-invasive tools, and few of them are biomarker panels, serum biomarkers, imaging biomarkers, fibrosis biomarkers, and others. The rise in research & development is likely to offer promising biomarkers for the accurate diagnosis of NASH condition in the future.
The global non-alcoholic steatohepatitis biomarkers market is driven by the surge in prevalence of NAFLD & NASH disease, hefty unmet needs in terms of disease epidemiology and available diagnostic and therapeutic tools, mount in demand for non-invasive diagnostic methods, rise in geriatric population, upward incidences of obesity and type 2 diabetes, awareness about diagnostic tools as well as the inclination of government focus toward proposing better healthcare services. These factors are probable to propel the non-alcoholic steatohepatitis (NASH) biomarkers market across the globe at a higher note in the precise timeframe.
The adoption of conventional techniques to address non-alcoholic steatohepatitis biomarkers such as biopsy is steadily declining owing to limitations such as sampling bias, and complications such as mortality, bleeding, pain, and poor acceptability. The demand for non-invasive techniques to treat NAFLD has observed steady growth over the past decade. Non-invasive techniques that have gained noteworthy popularity to combat NAFLD include NAFLD-based fibrosis, NASH, and steatosis, and more. In fact, the surge in demand for these non-invasive techniques is probable to boost the demand for NASH biomarkers during the assessment period.
At the same time, in recent times, many significant players operating in the global NASH biomarkers are progressively investigating the algorithms that consist of non-imaging and imaging biomarkers to identify fibrosis and minimize biopsies in clinical settings. Technological advancements, research, and development activities coupled with an elevated prevalence of NAFLD are some of the foremost factors that are likely to drive the expansion of the non-alcoholic steatohepatitis (NASH) biomarkers market during the assessment period.
Non-Alcoholic Steatohepatitis Biomarkers Market Segment Review
The global non-alcoholic steatohepatitis biomarkers market has been studied under the segments of type and end-user.
Depending on the type segment, the market included hepatic fibrosis biomarkers, serum biomarkers, oxidative stress biomarkers, apoptosis biomarkers, and others.
Depending on the end-user segment, the market included research institutes and academics, pharmaceutical companies and CROs, diagnostic centers, hospitals & clinics, and others. The pharmaceutical companies and CROs segment grabbed a market value of USD 226.7 million in 2018.
Non-Alcoholic Steatohepatitis Biomarkers Market Regional Aspect
Regionally, the global non-alcoholic steatohepatitis (NASH) biomarkers market has been studied among the regions of Europe, North America, Latin America, Asia Pacific, and Middle East & Africa. North America led the global non-alcoholic steatohepatitis (NASH) biomarkers market in 2018 and now has acquired a significant share of the global non-alcoholic steatohepatitis (NASH) biomarkers market. The growth has been attributed to the hefty patient pool suffering from NASH and NAFLD indication, along with escalating liver diseases. In fact, a considerable rise in prevalence of obesity and Type 2 diabetes, a rise in demand for a non-invasive diagnostic tool such as biomarkers as well as the adoption of emerging and innovative biomarkers are few major attributable factors for the NASH biomarkers market growth in the forecast period.
Non-Alcoholic Steatohepatitis Biomarkers Market Vendor Landscape
The prime vendors operating in the global non-alcoholic steatohepatitis (NASH) biomarkers market include Echosens (France), Cisbio (France), GENFIT (France), Enterome (France), NGM Biopharmaceuticals (US), Laboratory Corporation of America Holdings (US), Pacific Biomarkers (US), One Way Liver, SL (Spain), Perspectrum Diagnostics Ltd (UK), Regulus Therapeutics, Inc. (US), Quest Diagnostics, Shenzhen New Industries Biomedical Engineering Co., Ltd (China), Siemens Healthineers (Germany), and Xeptagen SpA (Italy).
Read More About this Report @ https://www.marketresearchfuture.com/reports/non-alcoholic-steatohepatitis-biomarkers-market-7984
April 2020: Sequoia-backed in-vitro diagnosis focused biomedicine company Shenzhen New Industries Biomedical Engineering Co., Ltd (also known as Snibe) has kicked off its IPO subscription exercise. It targeted to raise 1.29 billion yuan ($183 million) on the ChiNext board of the Shenzhen Stock Exchange.
NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312